Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score Matched Study of 980 Patients.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
Subgroup analysis was performed among patients according to the Up-to-7 criteria.
I · Intervention 중재 / 시술
among patients according to the Up-to-7 criteria
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The TACE group had a significantly higher overall response rate than the TAE group (33% vs 26%, P < .001). [CONCLUSIONS] TACE resulted in a higher response rate and longer OS compared with TAE as the initial treatment for intermediate-stage HCC.
[PURPOSE] To assess the effectiveness of transarterial bland embolization (TAE) compared with transarterial chemoembolization (TACE) therapy in the treatment of patients with intermediate-stage hepato
- p-value P < .001
- 95% CI 0.474-0.653
APA
Zhang H, Xu J, et al. (2025). Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score Matched Study of 980 Patients.. Journal of vascular and interventional radiology : JVIR, 36(11), 1812-1819. https://doi.org/10.1016/j.jvir.2025.06.014
MLA
Zhang H, et al.. "Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score Matched Study of 980 Patients.." Journal of vascular and interventional radiology : JVIR, vol. 36, no. 11, 2025, pp. 1812-1819.
PMID
41135980 ↗
Abstract 한글 요약
[PURPOSE] To assess the effectiveness of transarterial bland embolization (TAE) compared with transarterial chemoembolization (TACE) therapy in the treatment of patients with intermediate-stage hepatocellular carcinoma (HCC).
[MATERIALS AND METHODS] A total of 2,031 patients with intermediate-stage HCC were screened, and 1,246 patients who underwent TAE or TACE as the first-choice treatment were retrospectively analyzed and baseline-matched according to the 2 treatment methods. Subgroup analysis was performed among patients according to the Up-to-7 criteria. The primary endpoint was overall survival (OS).
[RESULTS] A total of 1,246 patients with HCC who underwent TAE or TACE were included; 720 patients underwent TACE, and 526 underwent TAE. The patients in the TAE group exhibited poorer liver function and a significantly higher rate of hepatitis B infection (P < .001) compared with the TACE group. After propensity score matching, 490 well-matched pairs of patients with intermediate-stage HCC were selected for analysis. Univariate analysis showed that TACE significantly prolonged patient survival compared with TAE (P < .001). The 1-, 2-, and 3-year OS rates were 75.9%, 58.9%, and 44.9% for the TACE group and 59.2%, 34.9%, and 23.8% for the TAE group. Multivariate analysis showed a hazard ratio of 0.556 (95% CI, 0.474-0.653; P < .001) for the TACE approach over the TAE approach for OS. The TACE group had a significantly higher overall response rate than the TAE group (33% vs 26%, P < .001).
[CONCLUSIONS] TACE resulted in a higher response rate and longer OS compared with TAE as the initial treatment for intermediate-stage HCC.
[MATERIALS AND METHODS] A total of 2,031 patients with intermediate-stage HCC were screened, and 1,246 patients who underwent TAE or TACE as the first-choice treatment were retrospectively analyzed and baseline-matched according to the 2 treatment methods. Subgroup analysis was performed among patients according to the Up-to-7 criteria. The primary endpoint was overall survival (OS).
[RESULTS] A total of 1,246 patients with HCC who underwent TAE or TACE were included; 720 patients underwent TACE, and 526 underwent TAE. The patients in the TAE group exhibited poorer liver function and a significantly higher rate of hepatitis B infection (P < .001) compared with the TACE group. After propensity score matching, 490 well-matched pairs of patients with intermediate-stage HCC were selected for analysis. Univariate analysis showed that TACE significantly prolonged patient survival compared with TAE (P < .001). The 1-, 2-, and 3-year OS rates were 75.9%, 58.9%, and 44.9% for the TACE group and 59.2%, 34.9%, and 23.8% for the TAE group. Multivariate analysis showed a hazard ratio of 0.556 (95% CI, 0.474-0.653; P < .001) for the TACE approach over the TAE approach for OS. The TACE group had a significantly higher overall response rate than the TAE group (33% vs 26%, P < .001).
[CONCLUSIONS] TACE resulted in a higher response rate and longer OS compared with TAE as the initial treatment for intermediate-stage HCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Use of Botulinum Toxin in Treating Rosacea: A Systematic Review.
- Coated oncolytic viruses based "double strike" strategy triggering CD19 CAR-T therapy in gastrointestinal tumors.
- Programmed death-ligand 1 correlates with acute influenza B virus infection.
- Application of P16/Ki-67 dual-staining for the detection of high-grade cervical lesions in the triage of patients with minor abnormal cytology: A meta-analysis.
- Genomic evolution of pancreatic cancer at single-cell resolution.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.